Nuvalent Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, has promoted Henry Pelish, Ph.D., to Chief Scientific Officer. In this role, Pelish will continue to oversee discovery and early-stage development activities. “This promotion reflects Henry’s significant contributions to establishing the cornerstone of our approach at Nuvalent: leveraging a deep expertise in chemistry and struc...